Short Interest in DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Increases By 28.4%

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) was the target of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 1,100,000 shares, a growth of 28.4% from the May 15th total of 856,900 shares. Approximately 2.8% of the company's stock are short sold. Based on an average daily volume of 99,000 shares, the short-interest ratio is currently 11.1 days.

Institutional Trading of DiaMedica Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Paragon Associates & Paragon Associates II Joint Venture boosted its stake in DiaMedica Therapeutics by 6.7% in the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 514,784 shares of the company's stock worth $2,795,000 after purchasing an additional 32,170 shares in the last quarter. Susquehanna International Group LLP boosted its stake in DiaMedica Therapeutics by 269.5% in the 4th quarter. Susquehanna International Group LLP now owns 374,845 shares of the company's stock worth $2,035,000 after purchasing an additional 273,395 shares in the last quarter. Northern Trust Corp boosted its stake in DiaMedica Therapeutics by 49.8% in the 4th quarter. Northern Trust Corp now owns 180,192 shares of the company's stock worth $978,000 after purchasing an additional 59,902 shares in the last quarter. Royal Bank of Canada boosted its stake in DiaMedica Therapeutics by 46,879.1% in the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company's stock worth $588,000 after purchasing an additional 154,701 shares in the last quarter. Finally, LPL Financial LLC boosted its stake in DiaMedica Therapeutics by 8.2% in the 4th quarter. LPL Financial LLC now owns 152,000 shares of the company's stock worth $825,000 after purchasing an additional 11,500 shares in the last quarter. 10.12% of the stock is currently owned by institutional investors and hedge funds.

DiaMedica Therapeutics Trading Down 5.5%

Shares of NASDAQ:DMAC traded down $0.21 during trading on Friday, reaching $3.61. The stock had a trading volume of 174,275 shares, compared to its average volume of 87,236. DiaMedica Therapeutics has a one year low of $2.14 and a one year high of $6.82. The company has a market capitalization of $154.80 million, a P/E ratio of -5.64 and a beta of 1.23. The firm's 50-day simple moving average is $3.96 and its 200 day simple moving average is $4.90.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.18) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.18). During the same quarter in the prior year, the firm earned ($0.14) earnings per share. Equities research analysts forecast that DiaMedica Therapeutics will post -0.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of DiaMedica Therapeutics in a research report on Thursday, May 29th.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.